News Article

Candesic is pleased to have advised global technology company Novanta on its growth strategy and diligence of medical device company Riverpoint Medical.

Novanta has now entered into a definitive agreement to acquire Riverpoint for an upfront cash consideration of $1.2bn, with a potential milestone payment of $250m due in the first quarter of 2027.

The Candesic team was led by Senior Partner Marc Kitten, assisted by Senior Engagement Manager Dr Chris Cassar.

Riverpoint Medical is a leading developer, designer, and manufacturer of medical devices focused on advanced surgical fibres and related technologies, providing strategic OEMs with private-label minimally invasive surgical consumables and instruments across high-growth end markets including sports medicine, trauma and cardiovascular surgery.

Congratulations to all involved in this successful transaction. We look forward to Riverpoint’s continued success under Novanta’s leadership.